Table 1.
Baseline Characteristics of Patients With Lung Cancer Being Treated With ICIs Who Received an mRNA Vaccine
| Variables | Taking ICIs |
|---|---|
| (N = 126) | |
| Sex, male; n (%) | 92 (73.0) |
| Age (y), median (IQR) | 71 (65–74) |
| Height (cm), median (IQR) | 165.0 (159.2–169.4) |
| Weight (kg), median (IQR) | 59.2 (51.9–68.4) |
| Body mass index, median (IQR) | 21.9 (19.5–24.9) |
| Past history of COVID-19, n (%) | 3 (2.4) |
| Vaccine, n (%) | |
| BNT162b2 | 124 (98.4) |
| mRNA-1273 | 2 (1.6) |
| Vaccination interval (d), median (IQR) | 21 (21–21) |
| Underlying autoimmune disease,a n (%) | 11 (8.7) |
| ECOG performance status, n (%) | |
| 0 | 63 (50.0) |
| 1 | 54 (42.9) |
| 2 | 9 (7.1) |
| ¾ | 0 (0) |
| Histologic subtype of lung cancer, n (%) | |
| Adenocarcinoma | 73 (57.9) |
| Squamous cell carcinoma | 38 (30.2) |
| Small cell carcinoma | 4 (3.2) |
| Others | 11 (8.7) |
| Clinical stage, n (%) | |
| Ⅲ | 32 (25.4) |
| Ⅳ | 73 (57.9) |
| Recurrent | 19 (15.1) |
| Others | 2 (1.6) |
| ICIs used during the doses of vaccine, including 4-wk prefirst vaccination and 4-wk postsecond vaccination | |
| Pembrolizumab, n (%) | 62 (49.2) |
| Immunotherapy (ICI monotherapy)/maintenance of ICI monotherapy after treatment including cytotoxic therapy/immunochemotherapy, n | 12/24/26 |
| Nivolumab, n (%) | 10 (7.9) |
| Immunotherapy (ICI monotherapy)/maintenance of ICI monotherapy after treatment including cytotoxic therapy/immunochemotherapy, n | 10/0/0 |
| Atezolizumab, n (%) | 28 (22.2) |
| Immunotherapy (ICI monotherapy)/maintenance of ICI monotherapy after treatment including cytotoxic therapy/immunochemotherapy, n | 11/8/9 |
| Durvalumab, n (%) | 21 (16.7) |
| Immunotherapy (ICI monotherapy)/maintenance of ICI monotherapy after treatment including cytotoxic therapy/immunochemotherapy, n | 0/20/1 |
| Nivolumab + ipilimumab, n (%) | 5 (4.0) |
| Immunotherapy (ICI monotherapy)/maintenance of ICI monotherapy after treatment including cytotoxic therapy/immunochemotherapy, n | 4/0/1 |
| Lines of treatment, median (IQR) | 1 (1–2) |
| Number of cycles of ICI received at first vaccine dose, median (IQR) | 8.5 (4.0–18.0) |
| ICI administration, n (%) | |
| Before first dose of vaccine | 122 (96.8) |
| Between two doses of vaccine | 3 (2.4) |
| After second dose of vaccine | 1 (0.8) |
| Interval between vaccine and ICI dose | |
| Immediately preceding ICI to first dose of vaccine (d), median (IQR) | 10.5 (6.0–17.0) |
| First dose of vaccine to ICI between two vaccine doses (d), median (IQR) | 10.0 (6.0–14.0) |
| ICI between two vaccine doses to second dose of vaccine (d), median (IQR) | 11.0 (6.0–15.0) |
| Second dose of vaccine to ICI just after the dose of vaccine (d), median (IQR) | 12.0 (7.0–17.3) |
| Observation period | |
| Time from the start of ICI treatment to the first dose of vaccine (d), median (IQR) | 208.0 (80.5–391.5) |
| Time from the first vaccine dose to end of observation (d), median (IQR) | 145.0 (116.2–164.0) |
COVID-19, coronavirus disease 2019; ICI, immune checkpoint inhibitor; IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group.
a
Disease (number of patients): Hashimoto’s disease (5) psoriasis (1), polymyalgia rheumatica (1), slowly progressive insulin-dependent diabetes mellitus (1), idiopathic thrombocytopenic purpura (1), rheumatoid arthritis (1), and SAPHO syndrome (1).